SARS-CoV-2 Spike-Specific T-Cell Responses in Patients With B-Cell Depletion Who Received Chimeric Antigen Receptor T-Cell Treatments

Kalpana Parvathaneni; Kyabeth Torres-Rodriguez; Wenzhao Meng; Wei-Ting Hwang; Noelle Frey; Ali Naji; Vijay G Bhoj

doi:10.1001/jamaoncol.2021.6030

SARS-CoV-2 Spike-Specific T-Cell Responses in Patients With B-Cell Depletion Who Received Chimeric Antigen Receptor T-Cell Treatments

JAMA Oncol. 2022 Jan 1;8(1):164-167. doi: 10.1001/jamaoncol.2021.6030.

Authors

Kalpana Parvathaneni^{1

2}, Kyabeth Torres-Rodriguez³, Wenzhao Meng¹, Wei-Ting Hwang⁴, Noelle Frey⁵, Ali Naji⁶, Vijay G Bhoj^{1

2}

Affiliations

¹ Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
² Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
³ Department of Microbiology, University of Pennsylvania, Philadelphia.
⁴ Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
⁵ Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
⁶ Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Abstract

This cohort study examines the ability of patients receiving chimeric antigen receptor T-cell treatments to mount T-cell immunity in response to messenger RNA vaccines for severe acute respiratory syndrome coronavirus 2 despite substantial B-cell depletion.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

B-Lymphocytes
COVID-19* / immunology
Humans
Immunotherapy, Adoptive*
Receptors, Chimeric Antigen
SARS-CoV-2
Spike Glycoprotein, Coronavirus / immunology*
T-Lymphocytes / immunology*

Substances

Receptors, Chimeric Antigen
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2